PDCD1 and neoplasm: A high rate of de novo somatic mutations leads to high levels of neoantigens, causing abundant tumor-infiltrating lymphocytes, which are counterbalanced by the increased expression of immune checkpoint molecules, such as PDCD1 and CD274 [13].